Navigation Links
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
Date:1/4/2011

SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin.  The protocol for the study has been cleared by the United States Food and Drug Administration (FDA) and Health Canada.  Patient screening has begun and patient dosing is expected to commence within the next several weeks.  In the study ANA598 will be tested in both treatment-naive patients and treatment-experienced patients who failed a prior course of therapy with interferon and ribavirin.  ANA598 is the Company's direct-acting antiviral, or DAA, being developed for the treatment of hepatitis C.

"We are excited to initiate this Phase IIb study of ANA598," said James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer.  "By establishing safety and efficacy in a greater number of patients, including those who have failed prior HCV treatment, we hope to position ANA598 as a highly attractive HCV agent ready for Phase III development."

Phase IIb Protocol Design

In the study, approximately 200 chronically infected genotype 1 hepatitis C patients are expected to receive ANA598 200 mg twice a day (bid) in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) (a current standard of care, or SOC) with a loading dose of 800 mg bid on day 1, while approximately 66 patients are to receive placebo and SOC.  Enrollment is expected to include approximately equal numbers of treatment-naive patients and patients who have failed a prior course of SOC, including difficult to treat prior null-responders.   The primary endpoint of the study is Sustained Virological Response 24 weeks after patients conclude all treatment, known as SVR24.  Anadys is c
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
4. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
6. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
7. Anadys Retains Lazard as Strategic Advisor
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- The American Association for Homecare (AAHomecare) is pleased ... joined the AAHomecare Corporate Partner Program. ... been actively involved in AAHomecare for much of the ... into a major global manufacturer of home medical equipment. ... increase efforts on behalf of the HME sector in ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Larry J. Merlo , President and CEO of CVS ... National Press Club in Washington, D.C. ... selling tobacco products and its leadership in driving the innovations ... changes in our health care system pose enormous challenges to ... "CVS Health has a truly unique combination of business assets ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
(Date:9/21/2014)... of the leading online stores of real and synthetic hair ... human hair lace wigs inspired by 6 famous celebrities. It’s ... latest celebrity hairstyles are. , For people who ... to choose from: a style of yaki straight lace wig, ... ombre red lace wig. People can go to the product ...
(Date:9/21/2014)... United-Kingdom (PRWEB) September 22, 2014 PhUSE ... Sweeney and Dr. Lilliam Rosario as keynote speakers for ... Following keynotes from Dr. Ben Goldacre in 2013 ... Professor Lord Winston in 2011 , PhUSE again presents ... who are passionate about advancement of clinical information. , ...
(Date:9/21/2014)... September 21, 2014 Waldorf Risk ... Management Portal designed for Diocesan risks. The portal ... to support effective risk management and loss control ... live coinciding with Waldorf’s exhibition at the Diocesan ... These applications were developed in collaboration with three ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... Cheap Hosting USA, one of the leading review websites, ... the best Reseller hosting suppliers in 2014. “It is ... these companies have outperformed their competitors on hosting features, ... the best web hosting at affordable rates,” the site’s ... reseller hosting is a very popular way for webmasters ...
Breaking Medicine News(10 mins):Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2
... at the University of Cincinnati (UC) suggests that ... process that can provide cells with nutrients from ... can protect tumor cells from chemotherapy, allowing them ... a hidden, dormant, metastatic state. In this ...
... NY It should be possible to significantly improve ... drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), ... cells with their immediate surroundings, called the tumor microenvironment. ... Cancer Cell , CSHL Assistant Professor Mikala Egeblad ...
... , MONDAY, April 16 (HealthDay News) -- The ... surgery increased drastically in 2011, according to the American ... augmentation procedures was greater than breast augmentation, Botox injections ... chin augmentation may include increased use of video-chat technology, ...
... Indiana University and the Regenstrief Institute have developed an ... the specific health needs of each patient in the ... new study, "Automated Primary Care Screening in Pediatric Waiting ... found that by personalizing and automating the patient ...
... the place where an estimated 30 percent of Americans die, there ... job at managing end of life care. A new study ... is starting a discussion over the need to create end of ... nursing homes with incentive to improve care. "Nursing homes are ...
... (April 16, 2012) Cancer is much more likely in the ... to fight the disease and the often-toxic side effects of treatment. ... Research Center at The University of Texas Health Science Center at ... work only in younger patients can be used to help the ...
Cached Medicine News:Health News:Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer 2Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 2Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 3Health News:Chin Implant Surgeries On the Rise in U.S. 2Health News:IU, Regenstrief automated system aims to improve child health 2Health News:IU, Regenstrief automated system aims to improve child health 3Health News:Study recommends ways to evaluate end-of-life care in nursing homes 2Health News:Study recommends ways to evaluate end-of-life care in nursing homes 3Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 2Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 3
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... is a high performance assay for the ... B with a simple, easy-to-use test that ... minutes. Assay advantages include superior performance with ... to 14-day viral culture enables you to ...
... The CHLAYMDIA OIA test delivers 100% ... results in 19 minutes. With ... not returning for follow-up, this assay ... which can contribute to detection and ...
... therapy and nerve block procedures, Cadwells ... has a precisely machined Trocar (beveled) ... attached 61-cm (24-in) lead wire. Needle ... patient use only. A starter kit ...
Medicine Products: